- Home
- WIX vs GMAB Comparison
WIX vs GMAB Comparison
Compare WIX & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIX
- GMAB
- Stock Information
- Founded
- WIX 2006
- GMAB 1999
- Country
- WIX Israel
- GMAB Denmark
- Employees
- WIX N/A
- GMAB N/A
- Industry
- WIX Computer Software: Programming Data Processing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WIX Technology
- GMAB Health Care
- Exchange
- WIX Nasdaq
- GMAB Nasdaq
- Market Cap
- WIX 12.1B
- GMAB 12.1B
- IPO Year
- WIX 2013
- GMAB N/A
- Fundamental
- Price
- WIX $198.11
- GMAB $22.34
- Analyst Decision
- WIX Strong Buy
- GMAB Buy
- Analyst Count
- WIX 17
- GMAB 9
- Target Price
- WIX $248.53
- GMAB $40.71
- AVG Volume (30 Days)
- WIX 864.2K
- GMAB 1.9M
- Earning Date
- WIX 02-19-2025
- GMAB 02-12-2025
- Dividend Yield
- WIX N/A
- GMAB N/A
- EPS Growth
- WIX 304.77
- GMAB 83.82
- EPS
- WIX 2.31
- GMAB 16.85
- Revenue
- WIX $1,760,650,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- WIX $13.98
- GMAB $18.78
- Revenue Next Year
- WIX $14.55
- GMAB $14.98
- P/E Ratio
- WIX $88.27
- GMAB $13.00
- Revenue Growth
- WIX 12.74
- GMAB 30.67
- 52 Week Low
- WIX $117.58
- GMAB $18.64
- 52 Week High
- WIX $247.11
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- WIX 29.95
- GMAB 65.39
- Support Level
- WIX $216.61
- GMAB $18.74
- Resistance Level
- WIX $239.73
- GMAB $22.55
- Average True Range (ATR)
- WIX 9.22
- GMAB 0.46
- MACD
- WIX -3.59
- GMAB 0.39
- Stochastic Oscillator
- WIX 1.47
- GMAB 94.64
About WIX Wix.com Ltd.
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.